Effect of dutasteride, tamsulosin and the combination on patient‐reported quality of life and treatment satisfaction in men with moderate‐to‐severe benign prostatic hyperplasia: 2‐year data from the CombAT trial
Open Access
- 11 March 2009
- journal article
- research article
- Published by Wiley in BJU International
- Vol. 103 (7) , 919-926
Abstract
OBJECTIVE: To investigate the effect of dutasteride and tamsulosin as combined therapy compared with each monotherapy for improving patient‐reported health outcomes in men with moderate‐to‐severe urinary symptoms and prostate enlargement, reporting the pre‐planned 2‐year analyses from the CombAT trial. PATIENTS AND METHODS: The CombAT study is an ongoing, international, double‐blind, randomized, parallel‐group trial. Men aged ≥50 years with a clinical diagnosis of benign prostatic hyperplasia (BPH), an International Prostate Symptom Score (IPSS) of ≥12 units, a prostate volume of ≥30 mL, a total serum prostate‐specific antigen level of 1.5–10 ng/mL and a peak urinary flow of >5 and ≤15 mL/s, with a minimum voided volume of ≥125 mL, were randomized to receive 0.5 mg dutasteride, 0.4 mg tamsulosin or the combination once daily for 4 years. Symptoms were assessed every 3 months. The primary endpoint at 2 years was the change in IPSS from baseline. Secondary endpoints included various measures of health outcomes, which included the BPH Impact Index (BII), IPSS Question 8 (Q8), and the Patient Perception of Study Medication (PPSM) questionnaire. RESULTS: Combined therapy resulted in significantly greater improvements in BII and IPSS Q8 from baseline than did dutasteride from 3 months and compared with tamsulosin from 9 months (BII) or 12 months (IPSS Q8). Assessments using the PPSM questionnaire showed that a significantly higher proportion of patients were satisfied with and would request dutasteride and tamsulosin combined therapy than with each monotherapy at 24 months. CONCLUSIONS: Dutasteride and tamsulosin combined therapy provides significantly greater improvements in patient‐reported quality of life and treatment satisfaction than both monotherapies at 2 years, following the trends for clinical improvements in symptom scores and peak urinary flow rates, in men with moderate‐to‐severe BPH symptoms.Keywords
This publication has 21 references indexed in Scilit:
- PUK21 THE PSYCHOMETRIC VALIDATION OF AN US ENGLISH SATISFACTION MEASURE IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIAValue in Health, 2008
- Understanding patient and physician perceptions of benign prostatic hyperplasia in Europe: The Prostate Research on Behaviour and Education (PROBE) SurveyInternational Journal Of Clinical Practice, 2007
- Public, patient, and professional attitudes towards the diagnosis and treatment of enlarged prostate: a landmark national US survey*International Journal Of Clinical Practice, 2006
- Baseline Factors as Predictors of Clinical Progression of Benign Prostatic Hyperplasia in Men Treated With PlaceboJournal of Urology, 2006
- Alfuzosin for Symptomatic Benign Prostatic Hyperplasia: Long-Term ExperienceJournal of Urology, 2006
- Improvements in benign prostatic hyperplasia‐specific quality of life with dutasteride, the novel dual 5α‐reductase inhibitorBJU International, 2003
- Concomitant Longitudinal Changes in Frequency of and Bother From Lower Urinary Tract Symptoms in Community Dwelling MenJournal of Urology, 2002
- THE IMPACT OF MEDICAL THERAPY ON BOTHER DUE TO SYMPTOMS, QUALITY OF LIFE AND GLOBAL OUTCOME, AND FACTORS PREDICTING RESPONSEJournal of Urology, 1998
- Benign Prostatic Hyperplasia Specific Health Status Measures in Clinical Research: How Much Change in the American Urological Association Symptom Index and the Benign Prostatic Hyperplasia Impact Index is Perceptible to Patients?Journal of Urology, 1995
- A population-based study of health care-seeking behavior for treatment of urinary symptoms. The Olmsted County Study of Urinary Symptoms and Health Status Among MenArchives of Family Medicine, 1993